QR Pharma, Rockefeller University Research Drug For Huntington’s Disease

By

photo credit: Pills via photopin (license)

QR Pharma, Inc. of Berwyn is collaborating with The Rockefeller University to develop a treatment for Huntington’s disease.

The collaboration will focus on preclinical research involving QR’s lead drug candidate, Posiphen®. Investigators at Rockefeller will conduct experiments in stem cell culture models of HD to determine if Posiphen lowers the levels of  toxic  protein in these cells, if it promotes differentiation into neuronal cells and, if it prolongs the cell life of the HD cells. Results from the collaboration could lead to clinical studies in HD patients.

“QR Pharma’s technology targets the mRNA of a number of proteins that are over expressed in several neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, Down Syndrome, and Huntington’s disease in a manner that has the potential to impact disease progression,” said Maria Maccecchini, Ph.D., CEO of QR Pharma.

The clinical-stage specialty pharmaceutical company is developing therapeutics with novel approaches to treat cognitive impairment in neurological disorders.

QR currently has three product development programs: Posiphen for early stage Alzheimer’s, Parkinson’s and Huntington’s disease, and BNC for advanced Alzheimer’s disease. QR has successfully completed Phase I clinical trials with Posiphen and is conducting other clinical and pre-clinical work in Traumatic Brain Injury for the US Army.

_______

Top photo credit: Pills via photopin (license)
 

Connect With Your Community

Subscribe to stay informed!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Advertisement
Creative Capital logo